Anti-Opioid Pathway Discovered via Forward Genetics Approach with C. elegans

GEN | August 20, 2019

Scientists at Scripps Research in Florida report that they have discovered a biological system that manages cells response to opioid drug exposure. The team said its discovery offers new ideas for improving the safety of the one of the most effective, and most abused, group of pain medications. In a paper Genetic behavioral screen identifies an orphan anti-opioid system published in Science, lead authors Kirill Martemyanov, PhD, and Brock Grill, PhD, described how they designed and implemented a new approach using a nematode worm for decoding the genetic network that controls actions of opioids in a nervous system. “Opioids target μ-opioid receptor (MOR) to produce unrivaled pain management but their addictive properties can lead to severe abuse. We developed a whole animal behavioral platform for unbiased discovery of genes influencing opioid responsiveness. Using forward genetics in C. elegans, we identified a conserved orphan receptor, GPR139, with anti-opioid activity,” the investigators wrote. “GPR139 is coexpressed with MOR in opioid-sensitive brain circuits, binds to MOR and inhibits signaling to G proteins. Deletion of GPR139 in mice enhanced opioid-induced inhibition of neuronal firing to modulate morphine-induced analgesia, reward, and withdrawal. Thus, GPR139 could be a useful target for increasing opioid safety. These results also demonstrate the potential of C. elegans as a scalable platform for genetic discovery of GPCR signaling principles.”

Spotlight

The world is on the cusp of an industrial revolution fueled by biotechnology and biomanufacturing. Emerging biological technologies are and will continue to transform the foundation of our physical world – everything from clothing, to plastics, to fuels, to concrete.

Spotlight

The world is on the cusp of an industrial revolution fueled by biotechnology and biomanufacturing. Emerging biological technologies are and will continue to transform the foundation of our physical world – everything from clothing, to plastics, to fuels, to concrete.

Related News

CELL AND GENE THERAPY, INDUSTRIAL IMPACT

Azenta Announces Launch of Cryo Store Pico

Azenta Life Sciences | February 28, 2023

On February 27, 2023, Azenta Life Sciences, a leading provider of life sciences solutions, announced the launch of its latest automated cryogenic storage system, the Cryo Store PicoTM. This new product is designed to store high-value biological samples used throughout various stages of the life sciences industry, from research and development to clinical use. Azenta is already known for providing innovative automated cryogenic solutions such as the BioStore™ III Cryo and the CryoPod™ Carrier, and the Pico is the latest addition to its lineup. The product offers automated cryogenic solutions that are configured for laboratory and clinical procedures. The Pico offers a variety of features for cell and gene therapy developers and manufacturers, including end-stage deployment in hospitals and clinics. It offers controlled access and traceability to support regulatory compliance with a compact footprint and is also user-friendly for laboratory personnel. Interested parties can order the Pico now, and a live demonstration will take place at the Society for Laboratory Automation and Screening (SLAS) 2023 International Conference in San Diego, California. Pico's Product Manager Erica Waller commented, "Pico takes our proven automation capabilities and scales it down for the lab or the clinic, bringing the sample integrity and process rigor of automation closer to the point of use," (Source – PR Newswire) About Azenta Life Sciences Azenta is a leading life sciences solutions provider that helps to accelerate the development and delivery of impactful therapies to market. The company offers a comprehensive suite of cold-chain sample management solutions and genomic services for areas such as clinical research, drug development and advanced cell therapies. These solutions are trusted by some of the top biotech, pharmaceutical, academic, and healthcare institutions worldwide. Headquartered in Chelmsford, MA, Azenta has a global presence with operations across Europe, North America, and Asia. The company is committed to providing reliable, innovative, and high-quality solutions to meet the needs of its clients in the life sciences industry.

Read More

MEDTECH, INDUSTRIAL IMPACT

Bio-Techne and CST Partner to Validate Simple Western Antibodies

Bio-Techne | February 15, 2023

On February 14, 2023, Bio-Techne Corporation and Cell Signaling Technology (CST) announced that CST antibodies now have Simple Western™ validation. This will make it easier for researchers from numerous disciplines to study essential molecular signaling pathways on a reliable and validated platform. Accurate data must be obtained quickly and efficiently in order to advance drug discovery and development. This continued collaboration will provide a broader menu of Simple Western validated antibodies for a variety of targets across several disciplines. Simple Western systems from ProteinSimple, a brand of Bio-Techne, are the only completely automated western blotting solutions for protein identification and characterization, with results available in as little as 3 hours. Cell Signaling Technology (CST) is a leading developer of antibodies and other related reagents for elucidating cell signaling pathways that govern cellular behavior and have an impact on human health. CST has finished assay validation and optimization for a variety of its antibodies on the Simple Western platform, making it easier than ever to develop new reliable and robust immunoassays for the quantification and detection of phospho and total proteins. When using CST primary antibodies with Simple Western validation, researchers can simply dilute the antibody to the appropriate dilution range found on the data sheet and product page. In addition, CST antibodies are Simple Western protocol compliant, which allows users to include these thoroughly validated antibodies into their existing workflows seamlessly. About Bio-Techne Founded in 1981, Bio-Techne Corporation is a pioneer in the development and manufacturing of high-quality purified proteins and reagent solutions, particularly antibodies, cytokines and growth factors, immunoassays, tissue culture reagents, biologically active small molecule compounds, and cell and gene therapy workflow solutions, including T-Cell activation technologies. It also develops and produces diagnostic products for OEM and clinical clients, such as FDA-regulated calibrators, controls, blood gas and clinical chemistry controls, and other reagents. The company’s products are essential components of scientific investigation into molecular diagnostics and biological processes, which disclose the diagnosis, nature, genesis, and course of certain diseases.

Read More

CELL AND GENE THERAPY, INDUSTRIAL IMPACT

Scientist.com Announces the Launch of Compliance Mobile App for iOS

Scientist.com | February 02, 2023

On February 1, 2023, Scientist.com, the biopharma industry's largest R&D marketplace, announced the release of a new iOS mobile app. The app provides a new, easy-to-use, on-the-go experience for purchase request approvals and compliance. In addition, iPhone users receive untethered notifications for accepting, delegating, and clarifying requests without needing to use their computers. The result is speedier approvals and fewer delays in scientific discovery. Scientist.com has spent the past fourteen years developing a digital marketplace that allows scientists to devote more time to science and less time to paperwork. The platform enables researchers to test more ideas in less time and at a lesser cost. It digitizes a company's complete research activities, automatically tracking purchases, contract management, payment processing, and generating business intelligence reports. Scientist.com Founder and CTO Chris Petersen commented, "One of the major barriers to drug discovery is the time it takes to ensure all compliance measures are met for a given research project, and understandably so." He added, "Our goal in building the Compliance Mobile App is to put compliance in the pocket of approvers, therefore minimizing the time it takes for researchers to move through the R&D process." (Source – Business Wire) Registered users of the Scientist.com platform can now get the Compliance Mobile App free from the Apple App Store About Scientist.com Founded in 2007, Scientist.com is the world's largest medical research marketplace. Its digital research platform combines a custom-built, cloud-native technology stack with a white-glove customer and scientific support, helping pharmaceutical scientists discover life-saving drugs in less time and at a lower cost. As a result, Scientist.com is accelerating and lowering the cost of medical research by connecting scientists and allowing them to exchange ideas and transact online effortlessly. The company now has a presence in enterprise marketplaces for 20 of the world's top 30 pharmaceutical firms, 80 biotechnology enterprises, and the National Institutes of Health in the United States (NIH).

Read More